Conditions: Healthy Subjects
Keywords: Alzheimer's disease
Allocation: RANDOMIZED | Intervention model: 
Enrollment: 55
Healthy volunteers: yes

Brief summary:
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.

Detailed description:

Arms:
arm 1: Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo). arm 2: Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979) arm 3: Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo) arm 4: Multiple dose administration to Healthy Elderly Subjects (PF-06751979) arm 5: Multiple dose administration to Healthy Elderly Subjects (Placebo)

Interventions: intervention 1: PF-06751979 single ascending dose intervention 2: Placebo single dose intervention 3: PF-06751979 multiple ascending dose intervention 4: Placebo multiple dose intervention 5: PF-06751979 multiple dose intervention 6: PF-06751979 multiple dose
Intervention descriptions: intervention 1: PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg. intervention 2: Matched Placebo solution/suspension administered as single dose. intervention 3: PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg. intervention 4: Matched Placebo (solution/suspension)administered daily for 14 consecutive days. intervention 5: PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg. intervention 6: Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.

Protocol document: